Kornimate/medical-research-clean huggingface dataset:
the effect of topical curcumin versus topical corticosteroid on management of oral lichen planus patients

Conditions: Oral Lichen Planus

Summary: introduce a new anti-inflammatory and antioxidant paste preparation (curcumin paste) in the management of oral lichen planus. * assess the efficacy of this preparation on pain, clinical parameter and the level of il-33 in saliva. * compare the outcome of new preparation with the gold standard treatment (corticosteroids).

two groups will be prepared then decision of which one take curcumin paste will be selected according to randomized numbers in a sequentially numbered, opaque, sealed envelope 1 group will take topical corticosteroid and 1 will take curcumin paste then il-33 level in saliva will be measured at the base line and at the end of 4th week pain and clinical parameters will be measured at 2nd and 4th week

Eligibility criteria:
inclusion criteria: * patients who will be clinically diagnosed as having atrophic \&/or erosive oral lichen planus. * patients with controlled diabetes and/or controlled hypertension will be included in the study. * patients with no history of taking corticosteroids for the last 6 months * patients who agrees to take medication. exclusion criteria: * pregnant and lactating ladies. * patients with history of topical steroids during last 2 months \& systemic steroids during last 6 months. * patients with recent dental filling associated with the lesion or associated with recent drug administration. * patient with uncontrolled diabetes, uncontrolled hypertension, or those with positive hcv ab or hbs ag.

Keywords: oral lichen planus curcumin il-33 corticosteroids
skin tests in cat allergic patients with cat dander samples obtained before and after vaccinating the cat

Conditions: Hypersensitivity

Summary: determination of allergenicity of cat dander samples obtained before and after vaccinating the cat


Eligibility criteria:
inclusion criteria: * informed consent as documented by signature (appendix informed consent form) * male or female between 18 years to 65 years * confirmed cat allergy (positive skin prick test) exclusion criteria: * diseases or medications, influencing the skin tests or impairing the correct conduct and evaluation of the study * history of anaphylactic reaction * pregnancy * skin irritations in test area * participation in another clinical trial within the last 30 days and during the present study

Keywords: cat allergy dander fel d 1 felis domesticus
effect of a female strength & conditioning specialist on high school girls' health

Conditions: Physical Inactivity; Low Physical Fitness

Summary: the majority of today's youth do not engage in enough physical activity (pa) to maintain good health. low pa levels are associated with poor health (e.g. diabetes, high blood pressure) and early mortality. girls are less likely than boys to be active, and their rates of participation drop off more steeply during adolescence. girls report many barriers to exercise, including transportation issues and feeling self-conscious about their appearance and abilities. school-based pa programs that try to improve health, mainly through aerobic exercise and education, have had a small effect to date. however, the few programs that included resistance training as the focus showed strong improvements in health related measures. in this project, we will examine the effect of a female strength and conditioning specialist on decreasing barriers and increasing the overall health of high school girls, with the delivery of in-school, girls-only resistance training programs. we will see if physical and mental health changes with the training, and how the presence of the s \& c specialist affects the girls' social interactions within the school. the results will help individuals in the education sector plan programs and services to improve overall youth and school health.


Eligibility criteria:
inclusion criteria: * grades 7 to 12 at grant park high school * do not participate on organized sports teams * self-report as not meeting the recommended amount of 60 min of moderate-vigorous physical activity per day exclusion criteria: * engaged in regular resistance training activities within the previous 6 months * health condition or injury that would put them at risk during testing/training

Keywords: resistance training; muscle strength
mmr at 6 months trial

Conditions: Meales-mumps-rubella Vaccine

Summary: randomised, double-blind clinical trial to test humoral and cellular immunogenicity, and potential in-direct beneficial effect of the mmrvaxpro-vaccine administered at 6 months of age


Eligibility criteria:
inclusion criteria: * gestational age of 32+ weeks. * birth weight of 1000+ grams. * signed informed consent from the parents. exclusion criteria: * immune-deficiency (primary or acquired) or -suppression. * intake of immune modulating medicine (including high doses of corticosteroids) (m-m-rvaxpro is not contraindicated in individuals who are receiving topical or low-dose parenteral corticosteroids, e.g. for asthma prophylaxis or replacement therapy). * signs of severe illness or major malformation. * no danish-speaking parent. * children with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion are excluded. * children with known fructose intolerance, thrombocytopenia or any coagulation disorder will be excluded. * children who received blood or plasma transfusions, or administration of human immune serum globulin within the last 3 months will be excluded. * further, children are excluded from the trial if any contraindication is suspected: history of hypersensitivity to any measles, mumps, or rubella vaccine, or to any of the excipients, including neomycin. * children with active untreated tuberculosis, blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic systems will be excluded.

Keywords: measles-mumps-rubella vaccine
safety and efficacy of autologous bone marrow stem cells in treating spinal cord injury

Conditions: Spinal Cord Injuries

Summary: the projected data related to the burden of spinal cord injuries induced limb paralysis in india is quite alarming. this is attributed to the rapid industrialization and economical development in the country. increase in vehicular traffic has caused numerous road traffic accidents. rapid increase in populations, development in the computer technology and real estate business lead to construction of huge buildings which indirectly adds to the injuries due to fall. spinal cord injuries could not be treated adequately with the prevailing treatment modalities. in view of this, there is definitely an urgent need for finding different methods of treatment for these patients who cannot undergo established modalities of treatment or these have been tried unsuccessfully. since a large number of these patients will loose their productive life and at the prime of their lives, one such alternate therapy, which seems to offer some promise, is "stem cell" therapy, which has been well studied and published in prestigious journals. in our present study, we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells surgically transplanted directly into the lesion site with glial scar resection for 8 indian patients of chronic spinal cord injury and intra-thecal injection for 4 indian patients of acute and subacute injury.


Eligibility criteria:
inclusion criteria: 1. must be able to give voluntary (patients may not be able to write) consent. 2. must be able to understand study information provided to him. 3. patients with complete spinal cord trans-section: at least post 6 months after spinal cord injury (in chronic patients), \< 2 weeks in acute category and 2-8 weeks in subacute patients. 4. the level of spinal cord injury must be between c4 and t12(neurological level) 5. spinal cord injury categorized in terms of asia impairment scale. 6. age should be between 20-55 years exclusion criteria: * mechanical ventilation due to neurological impairment * multiple level trauma * undetermined size and location of spinal cord injury * gunshot or other penetrating trauma to the spinal cord * longitudinal dimension of injury by mri is greater than 3spinal segments * associated severe head injury * more than 9cms long bone fracture * women who are pregnant or lactating * serious pre-existing medical conditions * disease or impairment that precludes adequate neurological examination. * should not have co-morbidities like diabetes, systemic hypertension etc. * severe co-morbidities/bed sores tests positive for infectious diseases deranged coagulation profile and hb \< 8mg/dl
fluoxetine vs. brief psychotherapy for major depression

Conditions: Major Depressive Disorder

Summary: in this study we compare two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. in addition to more traditional outcome measures, we also measure the densities of 5ht-1a and d-2 receptors before and after the treatment. the main hypothesis is that brief psychotherapy is as effective as fluoxetine.

this study is a randomized comparison of two treatments for major depression - fluoxetine and brief psychodynamic psychotherapy. the patients are recruited from occupational health services and suffer from mild to moderate major depressive disorder. the treatments last for 16 weeks. the main outcome measures include ham-d, bdi, sofas, rand-36. in addition to more traditional outcome measures, we also measure the densities of 5ht-1a and d-2 receptors before and after the treatment using positron emission tomography (pet) . the main hypothesis is that brief psychotherapy is as effective as fluoxetine, but differences between the treatments are seen in pet scanning.

Eligibility criteria:
inclusion criteria: * mdd (mild to moderate) * hdrs 15 or more, age 20-60 years * no treatment for preceding 4 months * no dsm-iv axis i or ii comorbidity * no severe somatic illness * no contraindications for fluoxetine treatment

Keywords: major depressive disorder fluoxetine short-term psychodynamic psychotherapy pet
validation of hausa oswestry disability index, numeric pain rating scale, roland-morris disability questionnaire, sf-12 health survey, pain catastrophizing scale, fear-avoidance beliefs questionnaire,global rating of change scale and back beliefs questionnaire in low back pain patients

Conditions: Chronic Low Back Pain

Summary: oswestry disability index (odi), numeric pain rating scale, roland-morris disability questionnaire (rmdq), sf-12 health survey, pain catastrophizing scale (pcs), fear-avoidance beliefs questionnaire (fabq), global rating of change scale and back beliefs questionnaire (bbq) are important and widely used validated patient self-reported measures commonly used in clinical trials and health research involving patients with low back pain (lbp). however, to date, validated hausa versions of these tools are unavailable for use despite not only hausa language is commonly spoken in nigeria but in other parts of the world. the purpose of this study is to perform, using evidence-based guidelines, translation, cultural adaptation and validation of the odi, nprs, rmdq, sf-12 health survey, fabq, pcs, groc and bbq into hausa language among patients with lbp in northern nigeria.

this study will test the psychometric properties (i.e validity; reliability, and ceiling effect) of the odi-h, nprs, rmdq-h, sf-12-h, fabq-h, pcs-h, groc and bbq-h in hausa-speaking patients with lbp. rural and urban participants with lbp will be recruited purposively. copies of the translated hausa versions of the nprs, odi, rmdq, sf-12, fabq, pcs, bbq as well as vas for pain and disability will be self or interviewer-administered. lumbopelvic mobility using finger-floor distance test (ffd) will be also measured. the hausa versions of the odi, nprs, rmdq, sf-12, fabq, pcs, groc and bbq will be administered again a week after. data will be analysed using descriptive, correlation, and factorial analysis on ibm spss (version 23.0) at alpha level of 0.05.

Eligibility criteria:
inclusion criteria: * male and female between 18 and 70 years old. * nonspecific low back pain lasting for more than 12 weeks. * resident in the selected rural and urban communities in kano state nigeria. * ability to read/understand english or hausa language. exclusion criteria: * previous history of back surgery. * spine pathology (e.g. tumor, infection, fracture) * severe cognitive impairment * impaired capacity to be interviewed * current pregnancy

Keywords: chronic low back pain oswestry disability index numeric pain rating scale roland morris disability questionnaire sf-12 health survey fear-avoidance beliefs questionnaire pain catastrophizing scale global rating of change scale back beliefs questionnaire
hct versus ct in elderly aml

Conditions: Acute Myeloid Leukemia

Summary: a study comparing conventional chemotherapy to low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors as consolidation therapy for older patients with aml in first complete remission.

the majority of patients with acute myelogenous leukaemia (aml) enter complete remission following induction therapy, but relapse despite consolidation and maintenance therapy. in response, post-remission treatment has been progressively intensified and results improved either by high-dose post-remission therapy with autologous hematopoietic cell transplantation (hct) or by allogeneic hct, which has the highest curative potential for patients with aml. given the toxicity of dose intensification and of allogeneic hct, however, only younger patients profit from this treatment approach

Eligibility criteria:
inclusion criteria: * age ≥ 60years and ≤ 75 years * primary or secondary aml as defined by who or refractory anemia with excess of blasts (raeb) * first complete remission following one or two cycles of induction chemotherapy * chemotherapy was administered according to current participating cooperative group protocols * karnofsky score ≥ 70 * written informed consent exclusion criteria: * aml fab m3 * hiv positivity * participation in another clinical trial without prior consent of the coordinating investigator, patients may exceptionally take part in a further study only if * the second study exclusively concerns induction therapy * consolidation cycle one and two are given according to the accredited study group policy * no investigational drugs are used post registration for the hct vs ct in eldery aml study. * documentation for the hct vs ct in eldery aml study is not compromised. second hand data from foreign study is not accepted

Keywords: hematopoietic cell transplantation acute myeloid leukemia first complete remission
safety and immunogenicity study of 20vpnc in healthy children 15 months through 17 years of age

Conditions: Pneumococcal Disease

Summary: this study is designed to evaluate the safety and immunogenicity of 20vpnc in healthy children 15 months through 17 years of age


Eligibility criteria:
inclusion criteria: * male or female children ≥15 months to \<18 years of age at the time of consent. * healthy children determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study. * for children \ 2 months before enrolment into the study exclusion criteria: * history of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) * major known congenital malformation or serious chronic disorder * other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results * previous vaccination with any investigational pneumococcal vaccine or with ppsv23, or planned receipt through study participation * cohorts 3 and 4: pregnant or breastfeeding female participants
poa retrospective repository

Conditions: Oncology; Solid Tumor, Adult

Summary: this repository is a multi-center, outcomes study designed to retrospectively collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing caris molecular intelligence® (cmi) services for the treatment of cancer. prior to enrolling a subject, the subject's physician will have made the independent decision whether or not to utilize the drug associations provided by cmi and made clinical treatment choices as appropriate. thus, data captured and reported provides a "real world" perspective on diagnosis, treatment, cost, and outcomes.

this repository is a multi-center, outcomes study designed to retrospectively collect data on the demographics, presentation, diagnosis, treatment, cost of associated care, quality of life, and outcomes of subjects utilizing caris molecular intelligence® (cmi) services for the treatment of cancer. prior to enrolling a subject, the subject's physician will have made the independent decision whether or not to utilize the drug associations provided by cmi and made clinical treatment choices as appropriate. thus, data captured and reported provides a "real world" perspective on diagnosis, treatment, cost, and outcomes. patients who have had cmi testing prior to the initial irb submission date of november 11, 2016 for the respective site would be eligible to have their treatment and treatment response data entered into the study database. all entered data would be de-identified. the patient's cmi biomarker results and treatment response data will be coupled together in order to allow the investigation of research questions concerning biomarker status and treatment response.

Eligibility criteria:
inclusion criteria: * subject' s age must be greater than or equal to 18 years and must have received cmi testing prior to the initial protocol irb submission date of november 11, 2016. exclusion criteria: * due to the complexity of state and federal requirements governing the participation of prisoners in research, prisoners-patients shall not be approached for participation.

Keywords: molecular profiling biomarker analysis outcomes database
comparison of exenatide taken before lunch and dinner with before breakfast and dinner in patients with type 2 diabetes

Conditions: Type 2 Diabetes

Summary: this trial is designed to compare the effects of twice-daily (before lunch and before dinner) exenatide plus oral antidiabetic (oad) agents and twice-daily (before breakfast and before dinner) exenatide plus oad with respect to glycemic control (hba1c) in patients with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * diagnosed with type 2 diabetes. * have been treated with one of the following treatment regimens for at least three months prior to screening: \*metformin alone; \*sulfonylurea (su) alone; \*thiazolidinedione (tzd) alone; \*a combination of metformin and su; \*a combination of metformin and tzd. * hba1c between 7.1% and 10.0%, inclusive. * body mass index (bmi) \> 25 kg/m\^2 and \< 45 kg/m\^2 exclusion criteria: * have participated in an interventional, medical, surgical, or pharmaceutical study (a study in which an experimental drug, medical, or surgical treatment was given) within 30 days prior to screening. * have characteristics contraindicating metformin, su, or tzd use. * are receiving chronic (lasting longer than 2 weeks) systemic glucocorticoid therapy (excluding topical and inhaled preparations) or have received such therapy within 2 weeks immediately prior to screening. * have used any prescription drug to promote weight loss within 3 months prior to screening. * are currently treated (for greater than 2 consecutive weeks) with any of the following excluded medications: \*insulin within 3 months prior to screening; \*alpha-glucosidase inhibitors within 3 months prior to screening; \*meglitinides within 3 months prior to screening; \*drugs that directly affect gastrointestinal motility

Keywords: diabetes exenatide lilly amylin
copper study - complications of polycystic ovary syndrome (pcos) pregnancy: evaluating risk

Conditions: Pregnancy Complications; Delivery Complications; Neonatal Complications

Summary: the copper study is a follow-up study of women diagnosed with polycystic ovary syndrome (pcos). women will be included pre-conceptional and followed-up until after delivery. the investigators will design a multivariate prediction model of pregnancy outcome in women with pcos with the intention to define intervention strategies for the future.

background of the study: pcos is a heterogeneous condition in which metabolic disturbances such as insulin resistance are common. pregnancies in women with pcos are reported to have an increased chance of being complicated by gestational diabetes, pregnancy induced hypertension and pre-eclampsia. subsequently their offspring are reported to have a lower birth weight and higher risk of admission to a neonatal intensive care unit. however, the cause of increased complication rate is not yet identified. there is evidence that intra-uterine conditions as well as pre- and periconception factors influence not only neonatal outcome, but also long-term health of the child. therefore early detection and treatment of pregnancy complications is important for both mother and child. in order to identify high risk pcos pregnancies, the specific effects of pcos on pregnancy in comparison to the background effects need further investigation. preconceptional risk assessment of pcos women is needed to improve antenatal health care and pregnancy outcome of pcos pregnancies in the future. objective of the study: to design a multivariate prediction model of pregnancy outcome in women with pcos with the intention to define intervention strategies for the future. study design: prospective multi-centre follow-up cohort study. method: women with pcos will be screened and included in the study pre-conceptionally. endocrinological values, glucose tolerance and ultrasound scan etc will be recorded. during pregnancy, blood samples will be stored regularly and glucose measurement will be done. post-partum the pregnancy outcome will be recorded.

Eligibility criteria:
inclusion criteria: * women with pcos * 18 to 40 years old, who wish to conceive. exclusion criteria: * women with anovulation that is not caused by pcos * women with a language barrier * women under 18 or over 40 years of age will be excluded from participation. other exclusion criteria are: * unresolved medical conditions * established type 1 diabetes.

Keywords: pcos polycystic ovary syndrome pregnancy complications gestational diabetes pre eclampsia prediction model pre conceptional